[HTML][HTML] Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma
N Puig, M Pintilie, T Seshadri, K Al-Farsi, T Nagy… - …, 2010 - ncbi.nlm.nih.gov
haematologica, 2010•ncbi.nlm.nih.gov
Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials
but its benefit in patients with primary refractory disease is less clear. Aiming to shed light on
this issue, we analyzed and compared the outcomes of patients with relapsed or refractory
Hodgkin's lymphoma treated with second-line chemotherapy and planned autologous stem-
cell transplantation.
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials
but its benefit in patients with primary refractory disease is less clear. Aiming to shed light on
this issue, we analyzed and compared the outcomes of patients with relapsed or refractory
Hodgkin's lymphoma treated with second-line chemotherapy and planned autologous stem-
cell transplantation.
Abstract
Background
The use of high-dose chemotherapy and autologous stem-cell transplantation in patients with relapsed Hodgkin’s lymphoma is supported by two randomized clinical trials but its benefit in patients with primary refractory disease is less clear. Aiming to shed light on this issue, we analyzed and compared the outcomes of patients with relapsed or refractory Hodgkin’s lymphoma treated with second-line chemotherapy and planned autologous stem-cell transplantation.
ncbi.nlm.nih.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果